neuro-primary-mental-health-2017-scientifictracks

5 / 22

Page 22
Notes:
allied
academies
17th International Conference on 4 th International Conference on
NEUROLOGY AND NEUROSCIENCE & MENTAL HEALTH AND PRIMARY CARE
October 16-18, 2017 | Toronto, Canada
J Neurol Neurorehabil Res 2017 | Volume 2 Issue 3
Anti-neutral glycolipids antibodies-mediated neurological disorder, EMRN: A subtype of MS?
Tatsuro Mutoh, Shima S, Ueda A and Niimi Y
Fujita Health University, Japan
Multiple Sclerosis (MS) is mainly involved in central
nervous system (CNS) but not peripheral nervous
system (PNS), whereas chronic inflammatory demyelinating
polyradiculopathy (CIDP) is mainly involved in PNS but not
CNS. Recently, however, a new clinical disorder involving both
CNS and PNS is emerging called as encephalomyeloradiculo-
neuropathy (EMRN). Several years ago, we discovered new
type autoantibodies against neutral glycolipids in sera and
cerebrospinal fluid (CSF) from these patients and the titers
of these autoantibodies were well correlated with disease
status (Neurology 2014), where we proposed that these
autoantibodies can be served as a surrogate marker for
EMRN. Since then, we have collected more than 20 similar
cases at our department and other cases from abroad
and all over Japan. The clinical phenotypes seem rather
broad; some developed CNS impairment first followed
by PNS involvements, others vice versa. There was no
gender preponderance and most cases exhibit autonomic
dysfunction. Among autoantibodies against neutral
glycolipids, anti-lactosylceramide antibodies (α-LacCer) were
most frequently detected. Previous studies have shown that
α-LacCer activate inflammatory responses in neutrophils.
We will discuss their biochemical and immunological actions
on neuronal and astroglial cells as well as detailed clinical
pictures of EMRN patients. The data strongly suggest that
these autoantibodies against neutral glycolipids profound
biological impacts on neuronal cells as well as glial cells in
culture.
Speaker Biography
Tatsuro Mutoh has completed his MD and PhD degrees from Nagoya University School
of Medicine, Japan in 1980 and 1986, respectively. He was appointed as Assistant Prof.
at Fukui Medical School in 1986. Then, he moved to National Institute of Health (NIH),
NICHD, USA as a Visiting Fellow from 1987-1990, where he purified novel nerve growth
factor-responsive protein kinases. He was promoted to Full Professor and Chairman
at Department of Neurology, Fujita Health University, Japan in 2006. His expertise is
Neuroglycobiology, protein-lipid interaction, and neuroimmunology. He has been
acting as Board Member of Front Cell Neurosci, Front in Biosci, and so on.
e: